Therapeutic Solutions International Inc
Therapeutic Solutions International, Inc. focuses on immune modulation for the treatment of various specific diseases in the United States. The company develops a range of immune-modulatory agents to cancers, schizophrenia, suicidal ideation, and traumatic brain injury, as well as for daily health. Its flagship products consist of QuadraMune, a patented synergistic blend of pterostilbene, sulfora… Read more
Therapeutic Solutions International Inc (TSOI) - Net Assets
Latest net assets as of September 2024: $1.68 Million USD
Based on the latest financial reports, Therapeutic Solutions International Inc (TSOI) has net assets worth $1.68 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.60 Million) and total liabilities ($1.92 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.68 Million |
| % of Total Assets | 46.71% |
| Annual Growth Rate | 22.71% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 2134.15 |
Therapeutic Solutions International Inc - Net Assets Trend (2007–2023)
This chart illustrates how Therapeutic Solutions International Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Therapeutic Solutions International Inc (2007–2023)
The table below shows the annual net assets of Therapeutic Solutions International Inc from 2007 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $1.28 Million | -7.43% |
| 2022-12-31 | $1.38 Million | +272.03% |
| 2021-12-31 | $-804.98K | +54.73% |
| 2020-12-31 | $-1.78 Million | +12.63% |
| 2019-12-31 | $-2.04 Million | -12.40% |
| 2018-12-31 | $-1.81 Million | -37.75% |
| 2017-12-31 | $-1.31 Million | -100.72% |
| 2016-12-31 | $-654.83K | -398.78% |
| 2015-12-31 | $-131.29K | 0.00% |
| 2014-12-31 | $-131.29K | +77.18% |
| 2013-12-31 | $-575.36K | -198.27% |
| 2012-12-31 | $-192.90K | -163.79% |
| 2011-12-31 | $302.38K | +1181.25% |
| 2010-12-31 | $-27.97K | -109.31% |
| 2009-12-31 | $300.25K | +5241.67% |
| 2008-12-31 | $5.62K | -88.41% |
| 2007-12-31 | $48.49K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Therapeutic Solutions International Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2030920400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.80 Million | 337.93% |
| Other Comprehensive Income | $-21.00K | -1.87% |
| Other Components | $17.67 Million | 1570.26% |
| Total Equity | $1.13 Million | 100.00% |
Therapeutic Solutions International Inc Competitors by Market Cap
The table below lists competitors of Therapeutic Solutions International Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Diagonal Bio AB
ST:DIABIO
|
$512.29K |
|
Lancaster Resources Inc.
PINK:LANRF
|
$512.30K |
|
INTERTEK GROUP
BE:IT1
|
$513.22K |
|
SOL S.P.A. EO 052
F:QOL
|
$513.52K |
|
FE BATTERY METALS CORP.
F:V95
|
$511.53K |
|
YANGAROO Inc
PINK:YOOIF
|
$511.39K |
|
Pasinex Resources Limited
PINK:PSXRF
|
$511.30K |
|
Brand Group (M.G) Ltd
TA:BRND
|
$511.08K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Therapeutic Solutions International Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 1,221,708 to 1,125,295, a change of -96,413 (-7.9%).
- Net loss of 2,169,814 reduced equity.
- New share issuances of 677,378 increased equity.
- Other comprehensive income decreased equity by 126,323.
- Other factors increased equity by 1,522,346.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.17 Million | -192.82% |
| Share Issuances | $677.38K | +60.2% |
| Other Comprehensive Income | $-126.32K | -11.23% |
| Other Changes | $1.52 Million | +135.28% |
| Total Change | $- | -7.89% |
Book Value vs Market Value Analysis
This analysis compares Therapeutic Solutions International Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.84x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.03x to 0.84x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $0.01 | $0.00 | x |
| 2008-12-31 | $0.00 | $0.00 | x |
| 2009-12-31 | $0.01 | $0.00 | x |
| 2010-12-31 | $0.00 | $0.00 | x |
| 2011-12-31 | $0.00 | $0.00 | x |
| 2012-12-31 | $0.00 | $0.00 | x |
| 2015-12-31 | $0.00 | $0.00 | x |
| 2016-12-31 | $0.00 | $0.00 | x |
| 2017-12-31 | $0.00 | $0.00 | x |
| 2018-12-31 | $0.00 | $0.00 | x |
| 2019-12-31 | $0.00 | $0.00 | x |
| 2020-12-31 | $0.00 | $0.00 | x |
| 2021-12-31 | $0.00 | $0.00 | x |
| 2022-12-31 | $0.00 | $0.00 | x |
| 2023-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Therapeutic Solutions International Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -192.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2191.86%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 2.93x
- Recent ROE (-192.82%) is below the historical average (-176.61%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -35.60% | 0.00% | 0.00x | 1.11x | $-22.11K |
| 2008 | -1628.68% | 0.00% | 0.00x | 2.29x | $-92.11K |
| 2009 | -512.13% | 0.00% | 0.00x | 1.04x | $-1.57 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-455.42K |
| 2011 | -321.02% | -57.51% | 0.49x | 11.44x | $-1.00 Million |
| 2012 | 0.00% | -36.75% | 10.87x | 0.00x | $-786.24K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-494.12K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-275.62K |
| 2015 | 0.00% | -107.39% | 1.34x | 0.00x | $-275.62K |
| 2016 | 0.00% | -30687.65% | 0.02x | 0.00x | $-520.96K |
| 2017 | 0.00% | -34916.59% | 0.11x | 0.00x | $-864.04K |
| 2018 | 0.00% | -53585.30% | 0.02x | 0.00x | $-1.69 Million |
| 2019 | 0.00% | -6173.20% | 0.09x | 0.00x | $-1.49 Million |
| 2020 | 0.00% | -3509.68% | 0.10x | 0.00x | $-2.02 Million |
| 2021 | 0.00% | -2029.00% | 0.09x | 0.00x | $-2.88 Million |
| 2022 | -312.18% | -1844.58% | 0.06x | 2.95x | $-3.94 Million |
| 2023 | -192.82% | -2191.86% | 0.03x | 2.93x | $-2.28 Million |
Industry Comparison
This section compares Therapeutic Solutions International Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Therapeutic Solutions International Inc (TSOI) | $1.68 Million | -35.60% | 1.14x | $512.27K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |